ArchiMed completed the acquisition of Diesse Diagnostica Senese from Orphee.

ArchiMed, an independent investment firm specialized in the healthcare industries, completed the acquisition of Diesse Diagnostica Senese, an Italian developer of innovative in vitro diagnostic systems, from Orphee. Financial terms were not disclosed. ″Following the change of ownership, the company will invest in helping the teams accelerate innovation and drive greater market penetration in Italy and foreign markets. In this context, a new board of directors has been appointed to introduce a team of specialists from the IVD industry with a proven ability to innovate and a solid commercial, and operational track record in Italy and international markets,″ Loïc Kubitza, ArchiMed Partner.